| [1] |
|
| [2] |
|
| [3] |
Kang N， Kim J， Kwon M，et al.Blockade of mTORC1 via rapamycin suppresses 27-hydroxycholestrol-induced inflammatory responses[J]. Int J Mol Sci， 2024， 25(19)：10381.DOI： 10.3390/ijms251910381.
|
| [4] |
Gherasie FA， Ciomag Ianula R， Gherasie LM.Drug-coated balloon PCI in different plaque morphologies：a narrative review[J]. Biomedicines， 2025， 13(6)：1472.DOI： 10.3390/biomedicines13061472.
|
| [5] |
|
| [6] |
Chen Y， Zeng Y， Zhu X，et al.Significant difference between sirolimus and paclitaxel nanoparticles in anti-proliferation effect in normoxia and hypoxia：The basis of better selection of atherosclerosis treatment[J]. Bioact Mater， 2021， 6(3)：880-889.DOI： 10.1016/j.bioactmat.2020.09.005.
|
| [7] |
Kawai K， Kolodgie FD， Kawakami R，et al.Vascular response，downstream effect，and pharmacokinetics after sirolimus- and paclitaxel-coated balloons in porcine coronary arteries[J]. Catheter Cardiovasc Interv， 2025， 105(6)：1434-1444.DOI： 10.1002/ccd.31482.
|
| [8] |
Clever YP， Peters D， Calisse J，et al.Novel sirolimus-coated balloon catheter：in vivo evaluation in a porcine coronary model[J]. Circ Cardiovasc Interv， 2016， 9(4)：e003543.DOI： 10.1161/CIRCINTERVENTIONS.115.003543.
|
| [9] |
|
| [10] |
Rao SV， O′Donoghue ML， Ruel M，et al.2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes：a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines[J]. Circulation， 2025， 151(13)：e771-e862.DOI： 10.1161/CIR.0000000000001309.
|
| [11] |
Vrints C， Andreotti F， Koskinas KC，et al.2024 ESC guidelines for the management of chronic coronary syndromes[J]. Eur Heart J， 2024， 45(36)：3415-3537.DOI： 10.1093/eurheartj/ehae177.
|
| [12] |
|
| [13] |
Synetos A， Koliastasis L， Ktenopoulos N，et al.Optical coherence tomography in acute coronary syndromes[J]. Rev Cardiovasc Med， 2025， 26(11)：43321.DOI： 10.31083/RCM43321.
|
| [14] |
Nguyen P， Seto A．Contemporary practices using intravascular imaging guidance with IVUS or OCT to optimize percutaneous coronary intervention[J]. Expert Rev Cardiovasc Ther， 2020， 18(2)：103-115.DOI： 10.1080/14779072.2020.1732207.
|
| [15] |
Viana SM， Zhang DM.Intravascular ultrasound guiding percutaneous coronary interventions in complex higher risk-indicated patients (CHIPs)：insight from clinical evidence[J]. Rev Cardiovasc Med， 2024， 25(12)：443.DOI： 10.31083/j.rcm2512443.
|
| [16] |
Gao XF， Ge Z， Kong XQ，et al.Intravascular ultrasound vs angiography-guided drug-coated balloon angioplasty：the ULTIMATE Ⅲ trial[J]. JACC Cardiovasc Interv， 2024， 17(13)：1519-1528.DOI： 10.1016/j.jcin.2024.04.014.
|
| [17] |
Holm NR， Andreasen LD， Neghabat O，et al.OCT or angiography guidance for PCI in complex bifurcation lesions[J]. N Engl J Med， 2023， 389(16)：1477-1487.DOI： 10.1056/NEJMoa2307770.
|
| [18] |
Kang DY， Ahn JM， Yun SC，et al.Guiding intervention for complex coronary lesions by optical coherence tomography or intravascular ultrasound[J]. J Am Coll Cardiol， 2024， 83(3)：401-413.DOI： 10.1016/j.jacc.2023.10.017.
|
| [19] |
Sarti A， Erriquez A， Dal Passo B，et al.Complete revascularization in older patients with myocardial infarction with or without complex nonculprit lesions [J]. Circ Cardiovasc Interv， 2025， 18(11)：e015902.DOI： 10.1161/circinterventions.125.015902.
|
| [20] |
Cocco M， Campo G， Guiducci V，et al.Complete vs culprit-only revascularization in older patients with myocardial infarction with or without ST-segment elevation[J]. J Am Coll Cardiol， 2024， 84(20)：2014-2022.DOI： 10.1016/j.jacc.2024.07.028.
|
| [21] |
Lin L， Ding Y， Tang Y，et al.Prognostic implications of increased and final quantitative flow ratios in patients treated with drug-coated balloons physiological evaluation after DCB in de novo lesions[J]. BMC Cardiovasc Disord， 2024， 24(1)：743.DOI： 10.1186/s12872-024-04413-w.
|
| [22] |
Koo BK， Hu X， Kang J，et al.Fractional flow reserve or intravascular ultrasonography to guide PCI[J]. N Engl J Med， 2022， 387(9)：779-789.DOI： 10.1056/NEJMoa2201546.
|
| [23] |
Ono M， Asano T， Noguchi M，et al.Cutting balloon versus standard balloon for lesion preparation of drug-coated balloon treatment in de-novo coronary artery lesions：rationale and design of the randomized NATURE trial[J]. Cardiovasc Revasc Med， 2025(81)：48-56.DOI： 10.1016/j.carrev.2025.03.009.
|
| [24] |
Kulyassa PM， Németh BT， Hizoh I，et al.The design and feasibility of optimal treatment for coronary drug-eluting stent in-stent restenosis (OPEN-ISR)-a prospective，randomised，multicentre clinical trial[J]. J Pers Med， 2025， 15(2)：60.DOI： 10.3390/jpm15020060.
|
| [25] |
Cortese B， Testa L， Heang TM，et al.Sirolimus-coated balloon in an all-comer population of coronary artery disease patients：the EASTBOURNE prospective registry[J]. JACC Cardiovasc Interv， 2023， 16(14)：1794-1803.DOI： 10.1016/j.jcin.2023.05.005.
|
| [26] |
Wańha W, Iwańczyk S, Januszek R, et al. Long-term outcomes following sirolimus-coated balloon or drug-eluting stents for treatment of in-stent restenosis[J]. Circ Cardiovasc Interv， 2024， 17(9)：e014064.DOI： 10.1161/CIRCINTERVENTIONS.124.014064.
|
| [27] |
Liu H， Li Y， Fu G，et al.Sirolimus- vs paclitaxel-coated balloon for the treatment of coronary in-stent restenosis：the SIBLINT-ISR randomized trial[J]. JACC Cardiovasc Interv， 2025， 18(8)：963-971.DOI： 10.1016/j.jcin.2024.12.024.
|
| [28] |
Oli PR， Shrestha DB， Dawadi S，et al.Comparison of different PCI strategies for coronary DES in-stent restenosis：a bayesian network meta-analysis[J]. J Soc Cardiovasc Angiogr Interv， 2025， 4(3Part A)：102428.DOI： 10.1016/j.jscai.2024.102428.
|
| [29] |
Jeger RV， Farah A， Ohlow MA，et al.Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2)：3-year follow-up of a randomised，non-inferiority trial[J]. Lancet， 2020， 396(10261)：1504-1510.DOI： 10.1016/S0140-6736(20)32173-5.
|
| [30] |
Tang Y, Qiao S, Su X, et al. Drug-coated balloon versus drug-eluting stent for small-vessel disease：the RESTORE SVD China randomized trial[J]. JACC Cardiovasc Interv， 2018， 11(23)：2381-2392.DOI： 10.1016/j.jcin.2018.09.009.
|
| [31] |
Tian J， Tang YD， Qiao S，et al.Two-year follow-up of a randomized multicenter study comparing a drug-coated balloon with a drug-eluting stent in native small coronary vessels：the RESTORE small vessel disease China trial[J]. Catheter Cardiovasc Interv， 2020(95 Suppl 1)：587-597.DOI： 10.1002/ccd.28705.
|
| [32] |
Cortese B, Testa G, Rivero F, et al. Long-term outcome of drug-coated balloon vs drug-eluting stent for small coronary vessels：PICCOLETO-Ⅱ 3-year follow-up[J]. JACC Cardiovasc Interv， 2023， 16(9)：1054-1061.DOI： 10.1016/j.jcin.2023.02.011.
|
| [33] |
Basavarajaiah S， Sharma V， Sticchi A，et al.Use of sirolimus-coated balloon in de novo coronary lesions; long-term clinical outcomes from a multi-center real-world population[J]. Catheter Cardiovasc Interv， 2024， 104(6)：1159-1167.DOI： 10.1002/ccd.31244.
|
| [34] |
Gao C， He X， Ouyang F，et al.Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I)：an open-label，randomised，non-inferiority trial[J]. Lancet， 2024， 404(10457)：1040-1050.DOI： 10.1016/S0140-6736(24)01594-0.
|
| [35] |
Gobbi C， Giangiacomi F， Merinopoulos I，et al.Drug coated balloon angioplasty for de novo coronary lesions in large vessels：a systematic review and meta-analysis[J]. Sci Rep， 2025， 15(1)：4921.DOI： 10.1038/s41598-025-85734-4.
|
| [36] |
Krackhardt F， Bonaventura K， Waliszewski M，et al.Effect of vessel diameter on the clinical benefits of drug-coated balloon angioplasty：insights from paclitaxel-coated balloon and polymer-free sirolimus-eluting stent studies[J/CD]. Clin Res Cardiol，2026-01-08[2026-05-20].DOI： 10.1007/s00392-025-02819-w.
|
| [37] |
Gobbi C， Giangiacomi F， Pasero G，et al.Efficacy and safety of sirolimus-coated balloon angioplasty in de novo lesions in large coronary vessels：a propensity score-matched study[J]. Catheter Cardiovasc Interv， 2025， 105(4)：861-869.DOI： 10.1002/ccd.31402.
|
| [38] |
Zhou Y， Hu Y， Zhao X，et al.Sirolimus-coated versus paclitaxel-coated balloons for bifurcated coronary lesions in the side branch：the SPACIOUS trial[J]. EuroIntervention， 2025， 21(6)：e307-e317.DOI： 10.4244/EIJ-D-24-00742.
|
| [39] |
Gao Q， Liu C， Xu G，et al.A prospective randomized open-label trial of sirolimus versus paclitaxel-coated balloons for the side branch of de novo coronary bifurcation lesion[J]. J Thorac Dis， 2025， 17(12)：10869-10879.DOI： 10.21037/jtd-2025-1243.
|
| [40] |
Fahrni G, Scheller B, Coslovsky M, et al. Drug-coated balloon versus drug-eluting stent in small coronary artery lesions：angiographic analysis from the BASKET-SMALL 2 trial[J]. Clin Res Cardiol， 2020， 109(9)：1114-1124.DOI： 10.1007/s00392-020-01603-2.
|
| [41] |
Caiazzo G， Oliva A， Testa L，et al.Sirolimus-coated balloon in all-comer population of coronary artery disease patients：the EASTBOURNE diabetes prospective registry[J]. Cardiovasc Diabetol， 2024， 23(1)：52.DOI： 10.1186/s12933-024-02139-9.
|
| [42] |
Mangieri A， Testa L， Heang TM，et al.Safety and efficacy of single antiplatelet therapy in a large cohort of patients treated with sirolimus-coated balloon：post hoc analysis from the prospective EASTBOURNE registry[J]. Cardiovasc Revasc Med， 2025(74)：52-56.DOI： 10.1016/j.carrev.2024.07.024.
|